Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

iwCLL 2019 | RESONATE-2: Ibrutinib for CLL 5-year follow-up

Alessandra Tedeschi • 21 Sep 2019
iwCLL 2019
Chronic Lymphocytic Leukemia Leukemia Ibrutinib
RESONATE

Alessandra Tedeschi, MD, Niguarda Cancer Center, Milan, Italy, gives an update on the RESONATE-2 study (NCT01722487) looking at the use of ibrutinib in patients with chronic lymphocytic leukemia (CLL) who are aged ≥65 years. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

More from Alessandra Tedeschi

iLLUMINATE 4-year follow up: obinutuzumab w/ ibrutinib vs w/ chlorambucil 1:25
iLLUMINATE 4-year follow up: obinutuzumab w/ ibrutinib vs w/ chlorambucil
Alessandra Tedeschi • 22 Sep 2019
Varying efficacies of combination and monotherapies in CLL 17:22
Varying efficacies of combination and monotherapies in CLL
Alessandra Tedeschi et al. • 21 Sep 2019
RESONATE: five-year follow-up of ibrutinib for CLL 1:52
RESONATE: five-year follow-up of ibrutinib for CLL
Alessandra Tedeschi • 15 Jun 2019
Waldenström’s Macroglobulinemia: frontline treatment 2:44
Waldenström’s Macroglobulinemia: frontline treatment
Alessandra Tedeschi • 15 Jun 2019

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals